Xiaoli Zhang, Ph.D., Kraig Labs' Chief Scientist Xiaoli Zhang, Ph.D., Kraig Labs Director of Molecular Biology ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang's leadership that are laying the foundation for t ...

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on key trial parameters – ...

CALGARY, Alberta, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Helium Evolution Incorporated (TSXV:HEVI) ("HEVI" or the "Company"), a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, announces that, in accordance with the automatic conversion provisions of the convertible note agreement as announced on August 26, 2025 with ENEOS Xplora USA Limited (“ENEOS USA”), the convertible note with a face value of $8.3 million (the “Note”) has been converted into common shares of t ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits Neumora plans to provide a comprehensive M4 franchise update by mid-2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today ...

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibilities of CEO. Mr Sheridan has returned to the position of CEO effective immediately and will guide the company through the final 2025 framework towards the target NDA filing in 2026 for AVERSA Fentanyl. AVERSA FENTANYL ...

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of it ...

TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Currency Exchange International, Corp. (the “Group” or “CXI”) (TSX: CXI; OTCQX: CURN), announced today that its board of directors (the “Board”) has unanimously approved the adoption of a “new generation” shareholder rights plan (the “Rights Plan”) pursuant to a shareholder rights plan agreement entered into with Computershare Trust Company of Canada, as rights agent, dated October 27, 2025 (the “Effective Date”). In alignment with good governance practices, the Ri ...

SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that it will release its 2025 third quarter financial results after the market closes on Monday, November 10, 2025, and host a conference call and simultaneous webcast at 5:00 p.m. ET (2:00 p.m. PT) that day. Both the call and webcast are open to the general public. On the ca ...

- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p<0.0001), and improvements were sustained at 12 months (p<0.0001) in BBP-418 treated individuals versus placebo - Average reduction in serum CK, a marker of muscle damage, of 82% change from baseline and stati ...

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025. Management will host a conference c ...